HTG Molecular Diagnostics Stock News

Low float penny stocks to watch. The post Best Penny Stocks To Buy?

Check these three penny stocks out for your watchlist The post Top Penny Stocks to Buy Today? 3 to Watch Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co

Which penny stocks are you watching right now? The post Best Penny Stocks to Buy Right Now?

Penny stocks to watch right now. The post Best Penny Stocks For July 2022?

TUCSON, Ariz., May 17, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide prof

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Monique Kosse - LifeSci Advisors John Lubniewski - President, CEO & Directo

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of -14.08% and 15.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for

Here's what you need to know about trading penny stocks on April 7th The post Trading Penny Stocks on April 7th? Fed News Causes Market Movement appeared first on Penny Stocks to Buy, Picks, News and

HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q4 2021 Results - Earnings Call Transcript

TUCSON, Ariz., Feb. 03, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM ) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has appointed Robert Spitale, Ph.D., Associate Director and Associate Dean of Research in the School of Pharmacy and Pharmaceutical Services at the University of California, Irvine (UC Irvine), to the HTG Therapeutics Scientific Advisory Board. Dr. Spitale is a chemical biologist with extensive training in genomics and cell biology, and is internationally recognized as a leader in the field of RNA structure and function. His research has focused on developing novel chemical and bioinformatic approaches to better understand how RNA molecules orchestrate gene expression pathways and contribute to disease pathology. "Dr. Spitale''s thorough understanding of the principles and mechanisms underlying RNA structure and the resulting impact on gene expression pathways can provide HTG with critical knowledge as we define our therapeutic targets addressing a wide range of medical needs," said Dr.

HTG Molecular Diagnostics Inc (HTGM) shares closed this week 20.4% lower than it did at the end of last week. The stock is currently down 21.6% year-to-date, down 29.9% over the past 12 months, and down 86.4% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Shares traded as high as $5.35 and as low as $4.17 this week.Shares closed 46.5% below its 52-week high and 33.2% above its 52-week low.Trading volume this week was 20.3% lower than the 10-day average and 59.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 127.3% The company's stock price performance over the past 12 months beats the peer average by -33.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Based on preliminary estimates, HTG Molecular Diagnostics (HTGM) expects FY21 revenue to be ~$8.9M, including ~$1.4M of HTG Transcriptome Panel ((HTP)) revenue.Consensus revenue

HTG Molecular Diagnostics Inc (HTGM) shares closed today 18.1% higher than it did at the end of yesterday. The stock is currently down 8.8% year-to-date, down 10.3% over the past 12 months, and down 84.7% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $4.50 and as low as $3.19 this week.Shares closed 45.0% below its 52-week high and 37.0% above its 52-week low.Trading volume this week was 67.7% lower than the 10-day average and 52.1% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -69.8% The company's stock price performance over the past 12 months beats the peer average by -68.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The stock price of HTG Molecular Diagnostics Inc (NASDAQ: HTGM) increased by over 20% during intraday trading today. This is why it happened.

HTG Molecular Diagnostics' (HTGM) CEO John Lubniewski on Q3 2021 Results - Earnings Call Transcript